Business
Phase 1B CHM CORE-NK trial advances to newly diagnosed AML
Phase 1B CHM CORE-NK trial advances to newly diagnosed AML
About this update from Chimeric Therapeutics Limited
Chimeric Therapeutics Ltd has released a press release. View Attachment
View stock analysis, news, and events for Chimeric Therapeutics Limited